Michael C Milone

List of Publications by Year
in descending order

113 papers	16,161 citations	53660 45 h-index	33814 99 g-index
115 all docs	115 docs citations	115 times ranked	17651 citing authors

#	Article	IF	Citations
1	Debulking SARS-CoV-2 in saliva using angiotensin converting enzyme 2 in chewing gum to decrease oral virus transmission and infection. Molecular Therapy, 2022, 30, 1966-1978.	3.7	39
2	Rapid manufacturing of non-activated potent CAR T cells. Nature Biomedical Engineering, 2022, 6, 118-128.	11.6	92
3	Enhancing CAR T function with the engineered secretion of C.Âperfringens neuraminidase. Molecular Therapy, 2022, 30, 1201-1214.	3.7	7
4	Trafficking and persistence of alloantigen-specific chimeric antigen receptor regulatory TÂcells in Cynomolgus macaque. Cell Reports Medicine, 2022, 3, 100614.	3.3	7
5	Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors. Nature Cancer, 2022, 3, 808-820.	5.7	21
6	Performance of Two Fentanyl Immunoassays against a Liquid Chromatographyâ€“Tandem Mass Spectrometry Method. Journal of Analytical Toxicology, 2021, 45, 117-123.	1.7	6
7	Pharmacology of Chimeric Antigen Receptorâ€“Modified T Cells. Annual Review of Pharmacology and Toxicology, 2021, 61, 805-829.	4.2	7
8	Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers. JAMA Internal Medicine, 2021, 181, 195.	2.6	168
9	Adoptive TÂcell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4. Molecular Therapy - Oncolytics, 2021, 20, 387-398.	2.0	20
10	Bâ€cell maturation antigen chimeric antigen receptor Tâ€cell reâ€expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitorâ€based combination therapy. British Journal of Haematology, 2021, 193, 851-855.	1.2	6
11	Evaluation of a Nanoparticle-Based Busulfan Immunoassay for Rapid Analysis on Routine Clinical Analyzers. Therapeutic Drug Monitoring, 2021, 43, 766-771.	1.0	4
12	Multi-Site Evaluation of Immunoassays for Antipsychotic Drug Measurement in Clinical Samples. journal of applied laboratory medicine, The, 2021, 6, 1541-1550.	0.6	5
13	Engineering-enhanced CAR T cells for improved cancer therapy. Nature Cancer, 2021, 2, 780-793.	5.7	60
14	High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms. Frontiers in Oncology, 2021, 11, 664236.	1.3	14
15	CAR T-Cells Depend on the Coupling of NADH Oxidation with ATP Production. Cells, 2021, 10, 2334.	1.8	7
16	The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. Clinical Cancer Research, 2021, 27, 6580-6590.	3.2	15
17	Perfecting CAR Engraftment to a Tee (Cell) through Characterization of Single Cell Transcriptome Product and Understanding Neurotoxicity. Blood, 2021, 138, 1707-1707.	0.6	0
18	Ontogeny of the Alloimmune Anti-Canine Factor VIII Inhibitor Response in Severe Hemophilia Î‘ Dogs. Blood, 2021, 138, 3173-3173.	0.6	0

#	Article	IF	Citations
19	A human orthogonal IL-2 and IL-2RÎ² system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia. Science Translational Medicine, 2021, 13, eabg6986.	5.8	64
20	Imaging CAR T Cell Trafficking with eDHFR as a PET Reporter Gene. Molecular Therapy, 2020, 28, 42-51.	3.7	70
21	Stable HLA antibodies following sustained CD19+ cell depletion implicate a long-lived plasma cell source. Blood Advances, 2020, 4, 4292-4295.	2.5	9
22	Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy. Clinical Cancer Research, 2020, 26, 6299-6309.	3.2	49
23	Enhancing Chimeric Antigen Receptor T Cell Anti-tumor Function through Advanced Media Design. Molecular Therapy - Methods and Clinical Development, 2020, 18, 595-606.	1.8	39
24	Ligand-Induced Degradation of a CAR Permits Reversible Remote Control of CAR T Cell Activity InÂVitro and InÂVivo. Molecular Therapy, 2020, 28, 1600-1613.	3.7	45
25	4-1BB costimulation promotes CAR T cell survival through noncanonical NF-ÎºB signaling. Science Signaling, 2020, 13, .	1.6	115
26	A Biomarker for Concussion: The Good, the Bad, and the Unknown. journal of applied laboratory medicine, The, 2020, 5, 170-182.	0.6	3
27	Testing the Specificity of Compounds Designed to Inhibit CPT1A in T Cells. Methods in Molecular Biology, 2020, 2097, 83-90.	0.4	2
28	Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. Journal of Clinical Investigation, 2020, 130, 6317-6324.	3.9	66
29	Human Orthogonal IL-2/IL-2RÎ² As a Tunable Approach to Enhance CD19-Speific CAR-T Cell Antitumor Activity. Blood, 2020, 136, 48-48.	0.6	1
30	An introduction to chimeric antigen receptor (CAR) Tâ€cell immunotherapy for human cancer. American Journal of Hematology, 2019, 94, S3-S9.	2.0	340
31	Repair of Tibial Plateau Fracture (Schatzker II). JBJS Essential Surgical Techniques, 2019, 9, e25.	0.3	8
32	T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Advances, 2019, 3, 2812-2815.	2.5	133
33	Commentary. Clinical Chemistry, 2019, 65, 1361-1361.	1.5	0
34	Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy. Journal of Visualized Experiments, 2019, , .	0.2	1
35	Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory. Clinical Chemistry, 2019, 65, 519-529.	1.5	4
36	B cell maturation antigenâ€“specific CAR T cells are clinically active in multiple myeloma. Journal of Clinical Investigation, 2019, 129, 2210-2221.	3.9	513

#	Article	IF	Citations
37	Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma. Blood, 2019, 134, 1909-1909.	0.6	4
38	Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors. Blood, 2019, 134, 622-622.	0.6	15
39	Prophylactic Itacitinib (INCB039110) for the Prevention of Cytokine Release Syndrome Induced By Chimeric Antigen Receptor T-Cells (CAR-T-cells) Therapy. Blood, 2019, 134, 1934-1934.	0.6	9
40	Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma. Blood, 2019, 134, 1863-1863.	0.6	13
41	Simple, 1-Day Manufacturing of Quiescent Chimeric Antigen Receptor T Cells for Adoptive Immunotherapy. Blood, 2019, 134, 4436-4436.	0.6	0
42	Powered and controlled T-cell production. Nature Biomedical Engineering, 2018, 2, 148-150.	11.6	5
43	The Pharmacology of T Cell Therapies. Molecular Therapy - Methods and Clinical Development, 2018, 8, 210-221.	1.8	78
44	Neurotoxicity Associated with a High-Affinity GD2 CARâ€"Response. Cancer Immunology Research, 2018, 6, 496-497.	1.6	14
45	The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations. Scientific Reports, 2018, 8, 6289.	1.6	119
46	Clinical use of lentiviral vectors. Leukemia, 2018, 32, 1529-1541.	3.3	519
47	CAR T cell immunotherapy for human cancer. Science, 2018, 359, 1361-1365.	6.0	1,968
48	High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model. Cancer Immunology Research, 2018, 6, 36-46.	1.6	192
49	Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients. American Journal of Kidney Diseases, 2018, 71, 315-326.	2.1	62
50	Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight, 2018, 3, .	2.3	140
51	Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Oncotarget, 2018, 9, 25764-25780.	0.8	61
52	False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy. Blood, 2018, 131, 2596-2598.	0.6	18
53	Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells. Cancer Immunology Research, 2018, 6, 1100-1109.	1.6	189
54	Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma. Blood, 2018, 132, 1886-1886.	0.6	19

#	Article	IF	Citations
55	PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells. Blood, 2018, 132, 1973-1973.	0.6	13
56	Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM). Blood, 2018, 132, 1974-1974.	0.6	10
57	Optimized FVIII-Domain-Based Chimeric Antigen Receptors to Specifically Target FVIII Inhibitor-Producing B Cells in Hemophilia a. Blood, 2018, 132, 2196-2196.	0.6	0
58	Improving T Cell Expansion with a Soft Touch. Nano Letters, 2017, 17, 821-826.	4.5	59
59	Studying Immunoreceptor Signaling in Human T Cells Using Electroporation of In Vitro Transcribed mRNA. Methods in Molecular Biology, 2017, 1584, 443-450.	0.4	1
60	Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood, 2016, 128, 360-370.	0.6	190
61	Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science, 2016, 353, 179-184.	6.0	468
62	High-Throughput Mechanobiology Screening Platform Using Micro- and Nanotopography. Nano Letters, 2016, 16, 2198-2204.	4.5	42
63	Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity, 2016, 44, 380-390.	6.6	811
64	The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. Clinical Cancer Research, 2016, 22, 2684-2696.	3.2	157
65	Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. Journal of Clinical Investigation, 2016, 126, 2642-2660.	3.9	81
66	B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study. Blood, 2016, 128, 1147-1147.	0.6	56
67	Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control. Blood, 2016, 128, 4549-4549.	0.6	2
68	Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide. Blood, 2016, 128, 5702-5702.	0.6	31
69	Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma. Blood, 2016, 128, 974-974.	0.6	28
70	Recovery of humoral immunity in patients with durable complete responses following chimeric antigen receptor modified t cells directed against CD19 (CTL019).. Journal of Clinical Oncology, 2016, 34, 7564-7564.	0.8	8
71	Engraftment of Human MDS Samples in Xenotransplanted Mice Depends on Human Cytokines but Not Mesenchymal Stem Cells (MSC). Blood, 2016, 128, 1980-1980.	0.6	0
72	516. Chimeric Antigen Receptors With Distinct Signaling Domains Can Reprogram T Cells. Molecular Therapy, 2015, 23, S206-S207.	3.7	0

#	Article	IF	Citations
73	21. Non-CD3-Based Chimeric Antigen Receptor (CARs) with Enhanced Anti-Tumor Activity in Solid Tumors. Molecular Therapy, 2015, 23, S10.	3.7	0
74	Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells. Cancer Immunology Research, 2015, 3, 356-367.	1.6	247
75	Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors. Cancer Immunology Research, 2015, 3, 815-826.	1.6	87
76	Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine, 2015, 7, 303ra139.	5.8	1,402
77	Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. Journal of Clinical Investigation, 2015, 125, 2293-2306.	3.9	319
78	The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Engraftment and Antitumor Responses Against Mantle Cell Lymphoma. Blood, 2015, 126, 704-704.	0.6	0
79	Loss of Programmed Death Ligand-1 Expression on Donor T Cells Lessens Acute Graft-Versus-Host Disease Lethality. Blood, 2015, 126, 147-147.	0.6	0
80	Breaking the Therapeutic Drug Monitoring Logistics Barrier. Clinical Chemistry, 2014, 60, 1471-1472.	1.5	1
81	Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptorâ€“Transduced Human T cells in Solid Tumors. Clinical Cancer Research, 2014, 20, 4262-4273.	3.2	339
82	Cross Talk between CD3 and CD28 Is Spatially Modulated by Protein Lateral Mobility. Molecular and Cellular Biology, 2014, 34, 955-964.	1.1	40
83	Humoral Immunity and Plasma Cell Changes in Patients Responding to CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T-Cell Adoptive Immunotherapy. Blood, 2014, 124, 1110-1110.	0.6	4
84	Signaling Domain of Chimeric Antigen Receptors Can Reprogram T Cells. Blood, 2014, 124, 551-551.	0.6	0
85	Chimeric Antigen Receptorâ€“Modified T Cells for Acute Lymphoid Leukemia. New England Journal of Medicine, 2013, 368, 1509-1518.	13.9	3,021
86	Investigative and clinical applications of synthetic immune synapses. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2013, 5, 75-85.	3.3	9
87	Eltrombopag and Serum of a Different Hue. Archives of Pathology and Laboratory Medicine, 2013, 137, 1175-1175.	1.2	17
88	Enhanced Function of Redirected Human T Cells Expressing Linker for Activation of T Cells That Is Resistant to Ubiquitylation. Human Gene Therapy, 2013, 24, 27-37.	1.4	18
89	Commentary. Clinical Chemistry, 2012, 58, 1635-1635.	1.5	1
90	F-actin polymerization and retrograde flow drive sustained PLCÎ³1 signaling during T cell activation. Journal of Cell Biology, 2012, 197, 775-787.	2.3	203

#	Article	IF	Citations
91	Laboratory Testing for Prescription Opioids. Journal of Medical Toxicology, 2012, 8, 408-416.	0.8	66
92	Substrate Rigidity Regulates Human T Cell Activation and Proliferation. Journal of Immunology, 2012, 189, 1330-1339.	0.4	230
93	Hyponatremia Associated With Levamisole-Adulterated Cocaine Use in Emergency Department Patients. Annals of Emergency Medicine, 2012, 60, 94-96.	0.3	12
94	Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL. Blood, 2012, 120, 717-717.	0.6	10
95	Commentary. Clinical Chemistry, 2011, 57, 674-674.	1.5	0
96	Increased risk of citrate reactions in patients with multiple myeloma during peripheral blood stem cell leukapheresis. Journal of Clinical Apheresis, 2010, 25, 188-194.	0.7	7
97	4-1BB and CD28 Signaling Plays a Synergistic Role in Redirecting Umbilical Cord Blood T Cells Against B-Cell Malignancies. Human Gene Therapy, 2010, 21, 75-86.	1.4	148
98	Commentary. Clinical Chemistry, 2010, 56, 1795-1796.	1.5	0
99	Lack of TNFÎ± expression protects anaplastic lymphoma kinase-positive T-cell lymphoma (ALK+ TCL) cells from apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 15843-15848.	3.3	19
100	Effect of a Variable Magnetic Field on Clinical Laboratory Testing. Clinical Chemistry, 2009, 55, 1249-1250.	1.5	1
101	Methotrexate Clearance by High-Flux Hemodialysis and Peritoneal Dialysis: A Case Report. American Journal of Kidney Diseases, 2009, 53, 871-874.	2.1	25
102	Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo. Molecular Therapy, 2009, 17, 1453-1464.	3.7	988
103	Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3360-3365.	3.3	758
104	Genetic engineering of T cells for adoptive immunotherapy. Immunologic Research, 2008, 42, 166-181.	1.3	59
105	Sleeping Beauty Transposonâ€mediated Engineering of Human Primary T Cells for Therapy of CD19+ Lymphoid Malignancies. Molecular Therapy, 2008, 16, 580-589.	3.7	130
106	Î³c-Signaling Cytokines Induce a Regulatory T Cell Phenotype in Malignant CD4+ T Lymphocytes. Journal of Immunology, 2008, 181, 2506-2512.	0.4	56
107	Therapeutic Drug Monitoring of Mycophenolic Acid. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 1062-1072.	2.2	74
108	Engineering Artificial Antigen-presenting Cells to Express a Diverse Array of Co-stimulatory Molecules. Molecular Therapy, 2007, 15, 981-988.	3.7	236

#	Article	IF	Citations
109	Tat-Functionalized Near-Infrared Emissive Polymersomes for Dendritic Cell Labeling. Bioconjugate Chemistry, 2007, 18, 31-40.	1.8	128
110	New Etiology Of Cocaine ???true??? Positive Drug Screen: Does South American Tea Really Contain Cocaine?. Therapeutic Drug Monitoring, 2005, 27, 253-254.	1.0	0
111	Adoptive immunotherapy: New ways to skin the cat?. Clinical Immunology, 2005, 117, 101-103.	1.4	11
112	Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood, 2004, 105, 994-996.	0.6	132
113	Functional deficiencies in two distinct interferon Î±-producing cell populations in peripheral blood mononuclear cells from human immunodeficiency virus seropositive patients. Journal of Leukocyte Biology, 1995, 57, 214-220.	1.5	39